ArticleAmerican journal of respiratory cell and molecular biology2014
Breaking the in vitro alveolar type II cell proliferation barrier while retaining ion transport properties.
Article in American journal of respiratory cell and molecular biology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 1 synthesis or guideline pooled it, 50 citations in OpenAlex.
- Systematic review of drug effects in humans and models with surfactant-processing disease.European respiratory review : an official journal of the European Respiratory Society · 2018Pooled it
- Combined trauma and toxic inhalation in war and disaster medicine: alveolar-capillary barrier failure and respiratory countermeasures.Critical care (London, England) · 2026Review
- Comprehensive characterization of human alveolar epithelial cells cultured for 28 days at the air-liquid interface.Scientific reports · 2025Article
- The use of human iPSC-derived alveolar organoids to explore SARS-CoV-2 variant infections and host responses.Journal of medical virology · 2024Article
- Development of an in vitro human alveolar epithelial air-liquid interface model using a small molecule inhibitor cocktail.BMC molecular and cell biology · 2024Article
- SLC26A9 in airways and intestine: secretion or absorption?Channels (Austin, Tex.) · 2023Review
- Article
- A Monoclonal Human Alveolar Epithelial Cell Line ("Arlo") with Pronounced Barrier Function for Studying Drug Permeability and Viral Infections.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023Article
- SARS-CoV-2 pathogenesis.Nature reviews. Microbiology · 2022Review
- Lung Extracellular Matrix Hydrogels Enhance Preservation of Type II Phenotype in Primary Alveolar Epithelial Cells.International journal of molecular sciences · 2022Article
- RNA-seq analysis of the human surfactant air-liquid interface culture reveals alveolar type II cell-like transcriptome.Molecular therapy. Methods & clinical development · 2022Article
- A novel alveolar epithelial cell sheet fabricated under feeder-free conditions for potential use in pulmonary regenerative therapy.Regenerative therapy · 2022Article
- Development of human alveolar epithelial cell models to study distal lung biology and disease.iScience · 2022Article
- Tissue-level alveolar epithelium model for recapitulating SARS-CoV-2 infection and cellular plasticity.Communications biology · 2022Article
- A New Immortalized Human Alveolar Epithelial Cell Model to Study Lung Injury and Toxicity on a Breathing Lung-On-Chip System.Frontiers in toxicology · 2022Article
- Culture and Imaging of Human Nasal Epithelial Organoids.Journal of visualized experiments : JoVE · 2021Article
- A Robust Protocol for Decellularized Human Lung Bioink Generation Amenable to 2D and 3D Lung Cell Culture.Cells · 2021Article
- Stem Cell-derived Respiratory Epithelial Cell Cultures as Human Disease Models.American journal of respiratory cell and molecular biology · 2021Review
- Advancing lung organoids for COVID-19 research.Disease models & mechanisms · 2021Review
- Versatile workflow for cell type-resolved transcriptional and epigenetic profiles from cryopreserved human lung.JCI insight · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 2 countries.
Funding
Abstract
Alveolar type (AT)I and ATII cells are central to maintaining normal alveolar fluid homeostasis. When disrupted, they contribute to the pathogenesis of acute lung injury (ALI) and acute respiratory distress syndrome. Research on ATII cells has been limited by the inability to propagate primary cells in vitro to study their specific functional properties. Moreover, primary ATII cells in vitro quickly transdifferentiate into nonproliferative "ATI-like" cells under traditional culture conditions. Recent studies have demonstrated that normal and tumor cells grown in culture with a combination of fibroblast (feeder cells) and a pharmacological Rho kinase inhibitor (Y-27632) exhibit indefinite cell proliferation that resembled a "conditionally reprogrammed cell" phenotype. Using this coculture system, we found that primary human ATII cells (1) proliferated at an exponential rate, (2) established epithelial colonies expressing ATII-specific and "ATI-like" mRNA and proteins after serial passage, (3) up-regulated genes important in cell proliferation and migration, and (4) on removal of feeder cells and Rho kinase inhibitor under air-liquid interface conditions, exhibited bioelectric and volume transport characteristics similar to freshly cultured ATII cells. Collectively, our results demonstrate that this novel coculture technique breaks the in vitro ATII cell proliferation barrier while retaining cell-specific functional properties. This work will allow for a significant increase in studies designed to elucidate ATII cell function with the goal of accelerating the development of novel therapies for alveolar diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.